Lung neuroendocrine tumors are catalogued in four categories by the World Health Organization (WHO 2004) classification. Its reproducibility and prognostic efficacy was disputed. The WHO 2010 classification of digestive neuroendocrine neoplasms is based on Ki67 proliferation assessment and proved prognostically effective. This study aims at comparing these two classifications and at defining a prognostic grading system for lung neuroendocrine tumors. The study included 399 patients who underwent surgery and with at least 1 year follow-up between 1989 and 2011. Data on 21 variables were collected, and performance of grading systems and their components was compared by Cox regression and multivariable analyses. All statistical tests were two-sided. At Cox analysis, WHO 2004 stratified patients into three major groups with statistically significant survival difference (typical carcinoid vs atypical carcinoid (AC), PZ0.021; AC vs large-cell/ small-cell lung neuroendocrine carcinomas, P!0.001). Optimal discrimination in three groups was observed by Ki67% (Ki67% cutoffs: G1 !4, G2 4-!25, G3 R25; G1 vs G2, PZ0.021; and G2 vs G3, P%0.001), mitotic count (G1 %2, G2 O2-47, G3 O47; G1 vs G2, P%0.001; and G2 vs G3, P%0.001), and presence of necrosis (G1 absent, G2 !10% of sample, G3 O10% of sample; G1 vs G2, P%0.001; and G2 vs G3, P%0.
Introduction
Lung neuroendocrine tumors include four different histologic subtypes, namely carcinoids (typical (TC) and atypical (AC)), large-cell neuroendocrine carcinoma (LCNEC), and small-cell lung carcinoma (SCLC), as defined by the World Health Organization (WHO) (Travis et al. 2004) . This classification mainly relies on morphology, with the help of mitotic count and necrosis assessment. Its prognostic value was validated by several studies (Asamura et al. 2006 , Righi et al. 2010 . Difficulty in its reproducibility was, however, denoted, with high interobserver variability (e.g. cytological features may be shared by AC and LCNEC and by LCNEC and SCLC making it difficult for diagnosis) and partial clinical efficacy (Travis et al. 1998 , Marchevsky et al. 2001 , Iyoda et al. 2007 , den Bakker et al. 2010 , Righi et al. 2010 , Ha et al. 2012 . The clinical significance of distinguishing between high-grade LCNEC and SCLC is not clear due to the overlapping survival curves usually observed (den Bakker et al. 2010 , Righi et al. 2010 , Ha et al. 2012 ). An effective grading system for digestive neuroendocrine neoplasms was recently introduced by the European Neuroendocrine Tumor Society (ENETS) and endorsed by the WHO and the American Joint Cancer Committee (Rindi et al. 2007 , Edge et al. 2010 ). This three-tiers system largely relies on the assessment of the proliferation marker, Ki67, and proved accurate and predictive in large tumor series (Scarpa et al. 2010 , Rindi et al. 2012 .
Here, we applied the digestive neuroendocrine neoplasms grading principles to lung neuroendocrine tumors, aiming that they may improve the current WHO 2004 classification. Accordingly, we competitively tested a large multicenter cohort of lung neuroendocrine tumors with the WHO 2004 classification of lung neuroendocrine cancer (from now on WHO 2004) vs the current WHO classification of digestive neuroendocrine neoplasms (from now on ENETS/WHO 2010 grading) and also with other relevant grading variables.
Subjects and methods

Type of study
This was an observational retrospective longitudinal study, with an embedded cross-sectional diagnostic validation study.
Data collection
The data collection included 399 lung neuroendocrine tumors from the following centers: Milano (MI, nZ159 neoplasms), Turin (TO, nZ90 neoplasms), Parma (PR, nZ73 neoplasms), and Rome (RM, nZ77 neoplasms). The study was approved by the Ethic Committee of the Università Cattolica -Policlinico A. Gemelli, as coordinating Center. The study enrollment criteria included the patient who underwent surgery for cancer and the patient who was under observation for at least 1 year during 1989-2011. Data on cases were consecutively collected in each center, with no significant change in the surgical approach and standard therapy approach during the observation time. We analyzed 21 variables: sex, age at diagnosis in years, diagnosis according to WHO 2004 (Travis et al. 2004 , status at follow-up, duration of follow-up in months, site, size, T (tumor), N (node), number of lymph nodes, M (metastases), the Union for International Cancer Control/the American Joint Committee on Cancer (UICC/AJCC) 2010 TNM stage (Travis et al. 2008 , Edge et al. 2010 , site of metastasis, mitosis/2 mm 2 , Ki67 index defined according to the ENETS/WHO 2010 grading definition , Ki67 index defined according to the Aperio automated computer-assisted quantitative method, Ki67 index defined according to the computerassisted manual count method (see below), necrosis, chemotherapy, radiotherapy, somatostatin analog (SSA) therapy, and Octreoscan somatostatin receptor (SSR) imaging. For the variable necrosis, as the WHO 2004 lacks a quantitative definition for focal or diffuse, we arbitrarily and tentatively defined as focal (also meant as punctate or spotty) when !10% of the sample or diffuse when equal or more than 10% of the sample. All deaths were recorded and were further classified as related to the underlying cancer by each hospital center, based on each patient's medical chart. Tumor-related death was defined as death directly or indirectly (e.g. therapy-related mortality) associated with the lung cancer. All data were cross-checked for inconsistencies by C Klersy and G Rindi. Every effort was made to minimize missing or incomplete data.
Ki67 assessment
Particular attention was paid to homogenous pathology assessment according to WHO 2004 and ENETS/WHO 2010 grading. All lung neuroendocrine tumors were reevaluated for consistency with the WHO 2004 classification (G Rindi, F Inzani, and G Fellegara) and discrepant cases, if present, discussed to reach consensus. The same investigators (F Inzani and G Rindi) performed the ENETS/WHO 2010 grading in the whole cohort. With the aim of obtaining the most homogenous data, Ki67 immunohistochemistry was centrally performed in the Immunohistochemistry Laboratory of the University of Parma by N Campanini with the MIB1 antibody. The Ki67 preparations of the entire cohort were assessed by the same investigators (G Rindi and F Inzani). With the aim of defining the most effective method for Ki67 determination in routine practice, a limited group of cases (nZ73) were tested using the following three methods: i) the expert eye count method; ii) the Aperio automated computerassisted quantitative method, and iii) the computerassisted manual count method. The expert eye count method consisted of counting under a microscope 500-2000 cells at 40! in areas of highest nuclear labeling as required by ENETS/WHO 2010 . The Aperio automated computer-assisted quantitative method consisted of scanning slides in the same areas at 40! using ScanScope XT (Aperio, Vista, CA, USA) and analyzing the digitized images with the Aperio Imagescope Software according to the manufacturer's indication. The computer-assisted manual count method consisted of taking a digital picture of the same areas and by manually counting on screen the Ki67 positive and negative nuclei using ImageJ Software (NIH, Bethesda, MA, USA; http:// rsbweb.nih.gov/ij/) (Schneider et al. 2012) . The expert eye and the Aperio-automated computer-assisted methods are commonly used in routine practice in pathology. The computer-assisted manual count method was considered as the reference (gold standard) method for quantitative Ki67% determination. This method adds the computer analysis power to the pathologists' cell discrimination efficacy.
Statistical analysis
A statistical analysis plan was defined and followed. Continuous data were described as the mean and S.D. or median and 25th-75th percentiles, and were compared by Kruskal-Wallis tests. Categorical data were described as counts and percentages and were compared by Fisher exact tests. For the Ki67 validation study, concordance between methods was evaluated with the Bland and Altman graphical method and the Lin's concordance correlation coefficient for Ki67 on a continuous scale and with the Kappa statistic after categorization according to tertiles of the distribution. The association of Ki67 eye and mitoses count was evaluated with the Spearman R and 95% CI. The optimal cutoffs for Ki67, maximizing both sensitivity and specificity to separate adjacent ENETS/WHO 2010 grading categories, were identified with the receiver operating curve (ROC) analysis.
The median follow-up was calculated by the inverse Kaplan-Meier method. Follow-up time was determined from the date of diagnosis to the date of death or the last follow-up for survivors. Overall survival and tumor-related death-free survival were estimated with the Kaplan-Meier method. For this latter analysis, patients dying from causes other than cancer were censored at their date of death. Death rates per 100 person-years and 95% CIs were reported. The Cox model was used to assess the prognostic value of a series of patient and tumor characteristics. Hazard ratios (HRs) and 95% CIs were also calculated. The proportional hazard assumption (Schoenfeld residuals) was always satisfied and model fit was assessed graphically with Cox-Snell residuals.
The performance of the grading systems was informally compared through Royston explained variation and the Harrell C discrimination statistics, in which the higher value was representative of better system performance. For this purpose, the model was fitted on a training sample and validated in a testing sample, after a random 2:1 split of the case series (Harrell et al. 1996 , Newson 2010 . Only cancers with data for all grading systems were used for comparative tests. All models were adjusted for stage. Given the collinearity of WHO 2004 and the ENETS/WHO 2010 grading, different multivariable models were fitted including either one of the two grading systems or the variables mitotic count, Ki67, and necrosis, while also controlling for other noncollinear predictors (age, sex, site, and stage). Model validation and informal comparisons were done as referred earlier.
All analyses were performed with Stata 12 (Stata Corporation, College Station, TX, USA) and Medcalc 12, for the ROC curve analysis, (MedCalc Software, Mariakerke, Belgium). A two-sided P value !0.05 was considered statistically significant.
Results
Clinical pathological findings
Three centers (TO, PR, and RM) contributed about 60% of this cohort (nZ240, 60.1%) with comparable numbers (PRZ73, TOZ90, and RMZ77). The higher contribution by the Milan center (nZ159, 39.8%) was likely due to its oncology referral practice. Patients were more often male (nZ245, 61%) with a median age of 63.2 years (Table 1; range 11-86 years). The four WHO 2004 classes were balanced, with similar frequencies for TC and SCLC (nZ113 (28%) and nZ108 (27%) respectively) ( Table 1) . No discrepant diagnosis was observed between centers. The distribution of sex per WHO 2004 classes was substantially similar for TC and AC (TC female 68, male 45; AC 44 and 40), with a net male predominance for highgrade cancers (LCNEC female 17, male 76; SCLC 24 and 83). Neoplasms were more often located in the right lung (nZ217, 60%; Table 1 ), and most in the upper lobe (nZ100, not shown), similar to the left lung (upper lobe, nZ70, not shown). The median tumor size was 2.8 cm (Table 1 ; mean 3.2G2 cm, range 0.5-13 cm). This was reflected by prevalent T1 and T2 status (175 and 150 cases respectively; Table 1 ). More than half of cases were void of lymph node deposit (N0Z215), with N1 status observed in about twice the cases than N2 (103 vs 55 respectively; Table 1 ), and only two cases with N3 status. Distant metastases (M1) were observed in 17 cases only, for 14 with available exact site definition (four in the liver, three in bones, two in contralateral lung, and one in the brain, pituitary, diaphragm, ovary, and thyroid). About 75% of cases were low stage (Stage I, nZ183, 50% and Stage II, nZ90, 24%) and 25% only were high stage (Stage III, nZ76, 20.8% and Stage IV, nZ17, 4.6%; Table 1 ) with similar distribution between WHO 2004 classes (not shown). Necrosis, either focal or diffuse, was observed in about 60% of tumors (nZ71 and nZ166 respectively; Table 1 ). When analyzed by the ENETS/WHO 2010 grading , about half tumors were G3 (nZ188, 49.5%; Table 1 ), about onethird G2 (nZ123, 32.4%; Table 1) , and the remaining few were G1 (nZ69, 18.2%; Table 1 ). Very limited information was available for standard chemotherapy, performed in 62 patients (three TC, ten AC, 18 LCNEC, and 31 SCLC), eight of which combined with radiotherapy and four with SSAs. Four further cases underwent also SSA therapy. Finally, information on SSR imaging with Octreoscan was available for 14 cases (three TC, five AC, two LCNEC, and one SCLC), of which three resulted negative (one TC, one AC, and one LCNEC).
Ki67 method validation
To validate the Ki67 method to be used for the entire cohort, we tested a fraction of present cases (nZ73) for agreement analysis of data obtained by the expert eye count, the Aperio automated and the computer-assisted manual count methods, the latter considered as the gold standard. The expert eye count method showed a concordance correlation coefficient vs the computer-assisted manual method (r cZ 0.98, 95% CIZ0.97-0.99; Fig. 1A ) better, but similar to the value observed with the Aperio automated method (r cZ 0.95, 95% CIZ0.94-0.97; Fig. 1B ) and comparable to the value observed when comparing the expert eye count vs the Aperio automated method (r cZ0.94, 95% CIZ0.92-0.96; Fig. 1C ). Both the expert eye and the Aperio methods were thus comparably effective as the gold standard. The expert eye count method, as the most practical in our hands, was adopted for the entire cohort.
Ki67-based grading system validation
The Ki67% distribution among WHO 2004 categories (TC, AC, LCNEC, and SCLC) was investigated. The Kruskal-Wallis equality of population rank test showed a statistically significant difference between the four WHO 2004 classes (P!0.001), with significant differences (after Bonferroni's correction) for pairwise comparisons between classes (TC vs AC, AC vs LCNC, and LCNC vs SCLC). The variable Ki67% was thus capable of distinguishing the four WHO 2004 classes in a statistically significant manner.
The specific Ki67% cutoff values discriminating the WHO 2004 classes were identified by ROC analysis. Between TC and AC classes, the Ki67% cutoff of O3% was recognized as discriminant (area under the ROC curve 0.712, moderate discrimination capacity; 95% CIZ0.64-0.78), with 60% sensitivity (95% CIZ48.4-70.8) and 78.70% specificity (95% CIZ69.8-86.0). Between AC and LCNEC, the cutoff of O20% demonstrated optimal discrimination power (area under ROC curve 0.99, optimal discrimination capacity; 95% CIZ0.98-1.00), with (95% CIZ7.87-10.86). The cumulative survival at 5 and 10 years was 62% (95% CIZ56-67) and 51% (95% CIZ44-58) respectively ( Fig. 2A ).
With the exception of stage, all grading variables tested were statistically significant predictors of survival. All predictors performed remarkably well and yielded comparable values, with relatively lower explained variation for necrosis (Royston explained variation 0.43, 95% CIZ0.25-0.65) and relatively higher value for mitosis in four quantiles (Royston explained variation 0.499, 95% CIZ0.307-0.738) ( Table 2 ). The discrimination ability was substantially similar, spanning from the relatively lower values of Ki67 in four ROC values or KI67 in three quantiles (Harrel C statistics 0.71, 95% CIZ0.63-0.78 for both), to the relatively higher value of mitosis in four quantiles (Harrel C statistics 0.78, 95% CIZ0.71-0.85) ( Table 2) .
Both the WHO 2004 and the ENETS/WHO 2010 grading failed to provide clear discrimination between categories ( Table 2 and Fig. 2B and C) . Similarly, when variables were tested in four tiers, all failed to display discrimination. In detail, mitosis in four quantiles failed to separate the last two classes (PZ0.54; Table 2 and Fig. 3A) , while Ki67, either in four quantiles or in four cutoffs identified by the ROC curve, failed to separate the first two classes (PZ0.15 and PZ0.26 respectively; Table 2 and Fig. 3B and C) , the latter one was also not discriminating between the last two (PZ0.35; Table 2 and Fig. 3C ). On the contrary, when tested in three tiers, either in tertiles (not shown for Ki67) or in three cutoffs identified by the ROC curve (Ki67 only), all variables displayed clear discrimination between categories (Table 2 and Fig. 4A, B and C) .
As for the Stage, grouping stages (Stages IA-IB grouped in Stage I; Stages IIA-IIB grouped in Stage II; and Stages IIIA-IIIB grouped in Stage III) yielded a low explained variation (Royston explained variation 0.08, 95% CIZ0.01-0.30), with relatively fair performance (Harrel C statistics 0.65, 95% CIZ0.57-0.73) ( Table 2) . Statistically significant differences between stages were only observed for grouped stages, but the extremely wide 95% CI of Stage 4 graphically obscured the statistically significant differences (Table 2 and Supplementary  Figure 1 , see section on supplementary data given at the end of this article).
A sensitivity analysis on the role of grading systems and grading variables on tumor-related death gave results essentially comparable with those of Table 2 , with similar, though slightly lower, Royston explained variation for survival prediction and discrimination ability by the Harrell C ( Supplementary Table 1 , see section on supplementary data given at the end of this article). Table 3 ). All models performed remarkably well, with well-explained variations, high shrinkage coefficient, and optimal discrimination at Harrell C statistic. In all models, the grading variables resulted as independent predictors of survival; however, only mitosis in three quantiles (Model B), necrosis (Model C), and Ki67 in three cutoffs identified by the ROC curve (Model E) retained the statistically significant separation capacity observed at univariable analysis (Table 2) . Of the other variables tested, older age and Stage in four groups (Stages III and IV only) consistently resulted as independent predictors of survival (Table 3) . Three further models with four tiers distribution (mitosis in four quantiles, Ki67 in four quantiles, and Ki67 in four cutoffs identified by the ROC curve) were also fitted and showed comparable performances, but confirmed to be ineffective for class separation (Models F-H, Supplementary Table 2 , see section on supplementary data given at the end of this article).
Generating and testing a new grading proposal
The three variables mentioned earlier (mitotic count, necrosis, and Ki67) with cutoff based on tertile distribution for mitosis and ROC curve values for Ki67 were used to generate a grading system (Table 4 ). To stratify patients accordingly, 348 cases with information of all variables and follow-up were stratified in tertiles for progressive death rate based on the association of the three parameters (Table 5 ). The grade definition was as follows: G1 if two of three markers were at level 1; G2 if two of three markers were at level 2; and G3 if two of three markers were at level 3. Cases were reclassified resulting in 134 G1, 59 G2, and 155 G3 and tested for survival analysis. All TC (nZ105) were reclassified as G1; of AC (nZ75), 29 were G1, 45 were G2, and one were G3; of LCNEC (nZ86), eight were G2 and 78 G3; of SCLC (nZ82), six were G2 and 76 were G3. At univariable analysis, the new grading performed remarkably well showing high HR (G1 vs G2 4.42, P!0.001, 95% CI 2.59-7.56; G1 vs G3 11.37, P!0.001, 95% CI 8.80-14.69; G2 vs G3 2.57, P!0.001, 95% CI 1.66-3.97), high Harrell's C statistics (0.76, Table 2 ; nZ355), (B) by Ki67% in four quantiles distribution (see Table 2 ; nZ368), and (C) by Ki67% in four cutoffs identified by the ROC curve distribution (see Table 2 ; nZ368): 95% CIs are shown. The number of patients at risk is given below the graphs. Kaplan-Meier survival curves for lung neuroendocrine tumors overall, by grading variables in three tiers. (A) The neoplasms were grouped by the presence of necrosis (see Table 2 ; nZ382), (B) by mitotic count in three quantiles distribution (see Table 2 ; nZ355), and (C) by Ki67% in three cutoffs identified by the ROC curve distribution (see Table 2 ; nZ368): 95% CIs are shown. The number of patients at risk is given below the graphs. 
Discussion
Grading is an essential instrument to predict cancer behavior. Its strength directly stems from morphological parameters, cheap and prognostically effective tools so far unsurpassed in the real-life management of patients. Grading efficacy depends on the degree of its reproducibility, its limit residing in its exquisitely qualitative nature. Our aim was to provide a clinically efficient grading system that may improve the current WHO 2004 classification (Travis et al. 2004) .
Here, we demonstrated that a three-tiers proliferationbased system is effective in predicting patient survival when tested in a large cohort of early-stage lung neuroendocrine cancers. Three evidences support this statement. First, WHO 2004 efficiently separated cancer patients as stratified in carcinoids (TC vs AC vs LCNEC/SCLC), but was ineffective in separating highgrade LCNEC vs SCLC (Fig. 1B) . This observation largely confirmed previously reported data (Marchevsky et al. 2001 , Asamura et al. 2006 , den Bakker et al. 2010 , Righi et al. 2010 , Ha et al. 2012 . Second, when using prognostically effective proliferation-associated tools like mitotic count and Ki67, a three-tiers system emerged as statistically efficient in predicting survival. These variables identified an intermediate-grade cancer-class which fares better than high-grade cancer patients and worse than low-grade ( Fig. 3B and C) . Third, the indirect morphological sign of malignancy, the presence of necrosis, similarly identified a three-tiers cancer patient stratification (Fig. 3A) . Both mitotic count and presence of necrosis are well-known malignancy-associated parameters and were used to build the WHO 2004 classification (Travis et al. 2004) . Interestingly, necrosis is recommended for reporting also in digestive neuroendocrine cancer implying its potential prognostic role (Klimstra 2013) .
The grading proposal for lung neuroendocrine tumors stemming from the present data and including such three parameters proved simple in application and extremely effective in patient stratification (Tables 4 and 5 and Fig. 5 ). Since generated within the present cohort, this grading system necessarily requires confirmation of its efficacy by studies on large, independent series. In specific, a larger sample will provide a more refined class separation. The current literature points to difficulties in accurately categorizing lung neuroendocrine cancers and supports the simplification of the WHO 2004 classification (Huang et al. 2002 , Asamura et al. 2006 , den Bakker et al. 2010 , Ha et al. 2012 ). In addition, separating high-grade lung neuroendocrine cancers in two categories seems so far void of prognostic significance, given that LCNEC and SCLC patients experience similar poor outcome. This new grading, if confirmed in its efficacy, may well overcome such pitfalls. So far Ki67 index is used for lung neuroendocrine cancer only for distinguishing TC/AC vs SCLC/LCNEC in small biopsy/cytology samples (Pelosi et al. 2005) . Several previous studies applied Ki67 index to lung neuroendocrine tumors, some of them to test its efficacy vs the WHO 2004 classification (see Walts et al. (2012) and references therein Walts et al. (2012) ). Contradictory results were obtained, likely reflecting the poor statistical power of investigated series and/or different Ki67 methods (Grimaldi et al. 2011 , Walts et al. 2012 , Zahel et al. 2012 . Our data indicate that, similar to what experienced for digestive neuroendocrine neoplasms, the introduction of a reproducible and objective parameter (the Ki67 proliferation index) may well provide an effective grading tool. In addition, here we provided evidence that at least two methods commonly adopted in pathology practice can be effectively used for Ki67 determination in neuroendocrine cancer, as demonstrated by others (Yang et al. 2011 , Tang et al. 2012 , Walts et al. 2012 . In particular, computerassisted methods like the Aperio, now available in major centers, can be safely adopted thus reducing the burden of the quantitative assessment, the major criticism so far moved to Ki67-based grading systems. Of interest, similar efficacy was demonstrated for Ki67 eyeballing assessment (Tang et al. 2012) . Finally, in light of previous evidence (Pelosi et al. 2005) , the use of Ki67 as further grading variable will hopefully be of help in establishing the diagnosis of intermediate malignant neuroendocrine cancer (TC vs AC) in small biopsies too.
The ENETS/WHO 2010 grading for digestive neuroendocrine neoplasms ) was ineffective in this large lung cohort (Fig. 2C ). This suggests that tissue-specific unknown features are relevant and require site-specific cutoffs for Ki67 and mitosis indexes, as recently observed for pancreas (Scarpa et al. 2010 , Rindi et al. 2012 . Nonetheless, our data are proof of concept that a three-tiers proliferation-based grading system may work for prognostic stratification of neuroendocrine cancer patients also outside the digestive system. This cohort was composed by early-stage, surgicalonly neuroendocrine tumors and not designed to test the efficacy of the staging system (Edge et al. 2010) . Nonetheless, the current staging accurately predicted patient survival for grouped Stages 1-3 ( Supplementary Figure 1) . The fact that no discrimination capacity was observed between sub-stage groups (Table 2 and Supplementary  Table 1 ) suggests the need for a simpler system for lung neuroendocrine tumors, as observed in the digestive tract (Scarpa et al. 2010 , Rindi et al. 2012 . This is the largest series ever used to test the efficacy of a Ki67-based grading system in lung neuroendocrine cancer. Though imperfect, this cohort is intended to be an acceptable compromise between patient selection bias and diagnostic accuracy. Indeed, our series was balanced in four equally populated lung neuroendocrine cancer classes according to WHO 2004, and provided effectively comparable surgical cases. The present series, however, suffers from the important exclusion of non-surgical, advanced, high-grade neuroendocrine cancer cases. Incidentally, our data indicate that 'early', high-grade neuroendocrine cancer patients may experience relatively long survival after curative oncological surgery.
The major limit of this study is its retrospective nature and consequent potentially non-homogenous data collection. Some variation in surgical approach at different Institution may have resulted in different efficacy, or different therapy policy in different centers may also have impacted the observed survival. A second important limit is the case selection based on curative surgery, making this cohort unsuitable for aims different from those investigated here. Finally, the present database did not contain information for recurrence -free survival, a relevant measure of low-grade neuroendocrine tumors. This aspect should be investigated in specifically designed future studies.
In conclusion, the present data indicate that Ki67 is an effective grading tool for lung neuroendocrine cancer. A three-tiers grading system based on Ki67 index, mitotic count, and presence of necrosis with cutoffs specifically generated for lung neuroendocrine tumors is prognostically effective and accurate, though in need of validation, supporting its introduction in the clinical practice.
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